Xinbang Pharmaceutical: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

Xinbang Pharmaceutical's net profit for 2025 increased by 18.65% to RMB 120 million, while its non-recurring net profit plummeted by half to RMB 87.11 million.

Operating cash flow increased by 15.36%.

lanjinger.comApr 21 10:54

Xinbang Pharmaceutical: 2025 Annual Report

SZSIApr 21 00:00 · Announcements

Xinbang Pharmaceutical: Summary of the 2025 Annual Report

SZSIApr 21 00:00 · Announcements

Xinbang Pharmaceutical (002390.SZ) and its subsidiaries are required to pay back taxes and late fees amounting to 50.7869 million yuan.

Gelonghui, January 25th: Xinbang Pharmaceutical (002390.SZ) announced that after a self-inspection, the company and its subsidiaries are required to pay additional taxes and late fees amounting to RMB 50.7869 million, of which RMB 2.6957 million is for the company itself and RMB 48.0912 million for its subsidiaries. This additional payment does not involve any administrative penalties.

Gelonghui FinanceJan 25 16:40

Xinbang Pharmaceutical (002390.SZ): Its subsidiary, Wudang Hospital affiliated with Guizhou Medical University, has a plastic surgery department.

Gelonghui, January 22nd - Xinbang Pharmaceutical (002390.SZ) stated on the investor interaction platform that its subsidiary, Guizhou Medical University Affiliated Wudang Hospital, has a plastic surgery department currently offering services such as eye and nose plastic surgery, injectable micro-plastic surgery, injectable hydrating needles, and photorejuvenation. Another subsidiary, Renhuai Xinyang Hospital Co., Ltd., has an aesthetic medicine department that integrates plastic surgery and skin beauty treatments into a comprehensive diagnosis and treatment system, currently offering services such as facial plastic surgery and skin management.

Gelonghui FinanceJan 22 09:02